Testosterone replacement therapy (TRT) has seen a surge in popularity over recent years, particularly with the expansion of specialized clinics and online platforms offering convenient access to hormone treatments. This rapid growth, however, has not been matched by the proliferation of comprehensive educational resources. As a result, many patients considering TRT are left with questions regarding its potential side effects—most notably, the risk of hair loss.
TRT aims to elevate testosterone levels in individuals experiencing deficiency, playing a critical role in various male characteristics, including hair growth. Testosterone itself is converted into dihydrotestosterone (DHT) through the action of the enzyme 5-alpha reductase. According to research, TRT can increase DHT concentrations by two to three times above normal levels, depending on the dosage and method of administration—whether transdermal applications such as gels and patches or intramuscular injections.
Dr. Blair Stocks, an assistant professor at Baylor Medicine’s Scott Department of Urology, explains that DHT is a more potent androgen than testosterone and binds strongly to androgen receptors in hair follicles. Persistently elevated DHT levels can result in the gradual shrinking of hair follicles—a phenomenon known as miniaturization—which leads to thinner hair strands and, eventually, complete cessation of visible hair production.
The most common form of hair loss among men is androgenetic alopecia (AGA), commonly referred to as male pattern baldness. AGA is primarily a genetic condition that progresses with age; it involves a genetically programmed shortening of the hair follicle growth phase over time, resulting in finer and lighter hair. While genetics play a central role, additional risk factors include family history on either parental side, age (with onset possible as early as puberty), and increased androgen levels from medications like TRT.
Managing Hair Loss Risks During TRT Therapy
Patients undergoing TRT who are concerned about hair loss should recognize that there is no universal solution; rather, management often requires a tailored combination of therapies. Dr. Oyetewa Asempa, assistant professor of dermatology and director of the Skin of Color Clinic at Baylor, recommends a multi-pronged approach to slowing hair loss associated with TRT.
Common strategies include stimulating hair growth with topical or oral minoxidil—the over-the-counter 5% foam or liquid formulations are widely available, but higher concentrations may be prescribed for increased efficacy. Additional therapies such as platelet-rich plasma injections, microneedling procedures, red-light treatments, and mesotherapy (direct scalp injections of minoxidil or other medications) may also benefit certain patients.
Pharmaceutical options like finasteride and dutasteride target the 5-alpha reductase enzyme to inhibit DHT production within hair follicles. When used at appropriate dosages alongside TRT—and with close collaboration between dermatology and urology specialists—these medications can mitigate activated testosterone’s impact on hair without compromising the broader benefits of hormone therapy. Adjustments to TRT dosage or formulation may also allow symptom control while reducing risks to hair health.
Dr. Stocks emphasizes the importance for prospective TRT patients to engage in thorough discussions with their healthcare providers before starting therapy. Critical topics include:
- Baseline hormone levels: Assessing DHT and testosterone levels prior to treatment helps set realistic expectations.
- Formulation differences: Transdermal forms like gels or patches may cause sharper increases in DHT compared to intramuscular injections, potentially influencing hair outcomes.
- Preventive options: Considering hair-preserving interventions such as finasteride before initiating TRT can help protect follicles from damage.
Ultimately, if hair loss is a concern for patients considering TRT, it is essential to communicate these worries with both prescribing physicians and dermatologists. Collaborative care ensures that medication regimens are optimized for each individual’s needs and risks. As Dr. Asempa notes, she never prescribes finasteride or dutasteride to a patient on TRT without first consulting the urology team; ongoing dialogue between specialists supports integrated treatment planning and patient referral when necessary.
In summary, while TRT therapy can elevate DHT levels and potentially accelerate hair loss—especially in genetically predisposed individuals—various preventive strategies exist. Patients should work closely with their healthcare teams to monitor hormone levels, explore appropriate therapies, and make informed decisions regarding their long-term health and wellbeing.
